<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03803163</url>
  </required_header>
  <id_info>
    <org_study_id>TCP-PH-101</org_study_id>
    <nct_id>NCT03803163</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male Volunteers</brief_title>
  <official_title>A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of TransCon PEG Treprostinil Administered as a Subcutaneous Injection in Healthy Adult Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascendis Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascendis Pharma A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the maximum tolerated dose (MTD) and assess safety and tolerability of
      escalating single doses of TransCon PEG treprostinil administered as a subcutaneous injection
      to healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Discontinued early due to local tolerance expectations not being met.
  </why_stopped>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>42 days</time_frame>
    <description>Safety and tolerability of single doses of TransCon Treprostinil treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax] of TransCon Treprostinil</measure>
    <time_frame>42 days</time_frame>
    <description>Pharmacokinetic profile of single doses of TransCon Treprostinil</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>TransCon Treprostinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TransCon Treprostinil</intervention_name>
    <arm_group_label>TransCon Treprostinil</arm_group_label>
    <other_name>ACP-009</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject gives voluntary written informed consent to participate in the study.

          2. Subject is a healthy male between the ages of 18 and 50 years, inclusive, at
             Screening.

          3. Subjects must weigh between 60 and 120 kg, inclusive, with a BMI between 19.0-32.0
             kg/m2, inclusive at Screening.

          4. Subject has a medical history, physical examination, vital signs, ECG and clinical
             laboratory results within normal limits or considered not clinically significant by
             the Investigator at Screening.

          5. Subject agrees to abstain from taking any prescription medication for 14 days prior to
             check-in and to abstain from taking any non-prescription medications (except
             multivitamins) or herbal supplements for 7 3 days prior to check-in Baseline until
             discharge from the study (unless prescribed by the Investigator to treat an AE).

          6. Subject agrees to abstain from consuming alcohol from three days prior to check-in and
             until discharge from the study.

          7. Subject agrees to refrain from strenuous exercise from check-in and until discharge
             from the study.

          8. Subject is able to communicate effectively with study personnel and be considered
             reliable, willing and cooperative in terms of compliance with the protocol
             requirements.

        Exclusion Criteria:

          1. Subject has any clinically relevant abnormality identified during the screening
             physical examination, 12-lead ECG, or laboratory examinations.

          2. Subject has a history of anaphylaxis, a previous documented hypersensitivity reaction,
             or a clinically significant idiosyncratic reaction to any drug.

          3. Subject has a clinically significant history of neurological, cardiovascular,
             respiratory, endocrine, hematological, hepatic, renal, gastrointestinal,
             genitourinary, pulmonary, and/or musculoskeletal disease; glaucoma; a psychiatric
             disorder, or any other chronic disease, whether controlled by medication or not.

          4. Subject has a history of postural hypotension, or unexplained syncope.

          5. Subject has a blood pressure that is less than 90 mmHg systolic or 50 mmHg diastolic
             at Screening or Baseline.

          6. Subject has a pulse rate that is greater than 90 bpm after sitting at rest for at
             least 5 minutes at Screening or Baseline.

          7. Subject has a history of hypertension.

          8. Subject has a blood pressure that is greater than 150 mmHg systolic or 90 mmHg
             diastolic at Screening or Baseline

          9. Subject has a predisposing condition that could interfere with the absorption,
             distribution, metabolism, or excretion of drugs.

         10. Subject has tested positive at the screening visit for HIV infection, HBsAg, or the
             HCV antibody.

         11. Subject currently uses tobacco or nicotine products or has a history of tobacco use
             within six months prior to Baseline.

         12. Subject has a history of alcohol abuse or a history of or current impairment of organ
             function reasonably related to alcohol abuse.

         13. Subject has a history of or current evidence of abuse of licit or illicit drugs,
             including a positive urine screen for drugs of abuse at Screening or Baseline.

         14. Subject has a history of abnormal bleeding tendencies.

         15. Subject has donated blood or plasma or has lost a significant volume of blood (greater
             than 450 mL) within four weeks prior to Baseline.

         16. Subject has participated in any investigational drug study within 30 days prior to
             their initial Screening visit.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>January 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>January 11, 2019</last_update_submitted>
  <last_update_submitted_qc>January 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

